Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: a prospective study.
Tirzepatide helps most patients lose substantial weight and improve blood sugar control, with most achieving meaningful weight loss within six months.
Tirzepatide achieved mean 18.04 kg (17.21%) weight loss at 6 months; 95.35% achieved >=5% and 60.47% >=15% weight loss at median dose 7.5 mg; significant glycaemic and lipid improvements; 3.7% dropout rate. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Prospective longitudinal observational cohort (n=107, 6 months)
- Category
- cardiovascular_metabolic
- Maturity
- Validated
- Journal
- Clinical Nutrition ESPEN
Why it surfaced
Real-world prospective confirmation of tirzepatide efficacy with comprehensive cardiometabolic outcomes; n=107, prospective design; directly watchlist-relevant for GLP-1/GIP, cardiometabolic.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.